Cannabis Sativa Inc (OTCMKTS:CBDS) showing dropped of -1.37% and closed at $6.50, after gaining total volume of 169,719.00 shares. Its earnings per share (EPS) is -$0.16 and its beta value stands at 18.81 points and has total market capitalization of $120.09 million and a total of 18.47 million outstanding shares.
Cannabis Sativa, Inc., through its subsidiaries, develops, manufactures, and sells herbal based skin care products in the United States and internationally. It offers herbal based line of products, including Go Deep, a deep penetrating healing salve that reduces pain and inflammation when massaged into muscles, ligaments, tendons, and joints; Go Deep EXTRA, a deep penetrating pain relief ointment for use in mitigating migraine and sinus headaches; Face Garden, an antioxidant and moisturizing cream for the face; Body Garden, a moisturizing body lotion; and Lip Garden, an emollient balm. The company also engages in the research, development, and licensing of natural cannabis products comprising cannabis formulations, edibles, topicals, strains, recipes, and delivery systems. It markets and sells its products through sales professionals, as well as through retailers and distributors. Cannabis Sativa, Inc. is based in Mesquite, Nevada.
Cannabis Science Inc (OTCMKTS:CBIS) decreased -1.94% closed at $0.0810 and traded with total volume of 10.92 million shares, while the average trading remained 26.73 million shares. During last trade its minimum price was $0.08 and it gained the highest price of $0.08. Its market capitalization was $188.09 million.
Cannabis Science Inc (CBIS) on March 30, 2017 announced that leader of global health information, Ms. Julia Royall, has been appointed to the Scientific Advisory Board of CBIS.
Ms. Royall is a Member of the Scientific Advisory Board. As a specialized consultant, she will provide advice and expertise on health information databases, management systems, and Internet technology. Julia Royall is a leader in health information and has been working in international health in Africa since 1990, with more than 40 years of professional experience in the communications field. Julia’s commitment is to bring together information and technology with partners, projects and funding, using a variety of media.
Ms. Royall was recruited to the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in 1997 to create a malaria research communications network (MIMCom) to support scientists in Africa as part of the Multilateral Initiative on Malaria. The first network of its kind, MIMCom comprised 27 research sites in 14 African countries and engaged over 30 partner organizations and institutions in the US, UK, Europe, and Africa.
As Chief of NLM’s Office of International Programs, she created innovative programs which focused on Africa and comprised outreach to medical librarians, medical journal editors, researchers, medical students, and health workers at the village level. In addition to adapting NLM databases for use in Africa, her work has encompassed a variety of media — from web-based interactive digital tutorials to posters and video. Under Ms. Royall’s leadership, NLM developed greater focus on global health by piloting demonstration projects which drew strength from one another and tied into NLM’s major programs and databases.
Earth Science Tech Inc (OTCMKTS:ETST) reported the surge of 10.49% and closed at $1.79, with the total traded volume of 18,538.00 shares. During last trade its minimum price was $1.65 and it gained its highest price of $1.85 and has a total of 40.91 million outstanding shares.
On March 14, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim Foster-Cunningham to the post of Project Manager for the MSN-2 medical device project; and Denis Babin of SDB Import/Export, Inc. as international marketing consultant for Cannabis Therapeutics and Earth Science Pharmaceutical products.
Ms. Foster-Cunningham’s immediate focus is preparatory phase of the pre-market clinical trial of the MSN-2 medical device. The MSN-2 device is a revolutionary medical instrument for the detection and diagnosis of Chlamydia and Gonorrhea, from previous announcement, (ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.)
Ms. Foster-Cunningham, whom holds a degree in sales and marketing, is recognized for her expertise in business networking and her solid business expertise. She is a sought-after speaker throughout the USA and Canada, delivering conferences on her proactive approach to general health and self-care. Passionate about individual sports, she is a half marathon runner and a triathlete. Always enthusiastic about transmitting her passion for health and business development, this project is “her new baby”.